Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Thrombomodulin alfa - Asahi Kasei Pharma Corp

Next Previous
Drug Profile

Thrombomodulin alfa - Asahi Kasei Pharma Corp

Alternative Names: ART-123; AT 908; Human recombinant thrombomodulin - Asahi Kasei Pharma Corp; Recombinant human soluble thrombomodulin - Asahi Kasei Pharma Corp; Recombinant thrombomodulin alfa - Asahi Kasei Pharma Corp; Recombinant thrombomodulin alpha - Asahi Kasei Pharma Corp; Recomodulin; Recomodulin® anticoagulant intravenous infusion 12800; rhs-TM - Asahi Kasei Pharma Corp; Thrombomodulin alpha - Asahi Kasei Pharma Corp; TMD-123

Latest Information Update: 11 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Asahi Kasei; Asahi Kasei Pharma Corp
  • Developer Asahi Kasei; Asahi Kasei Pharma America Corp; Asahi Kasei Pharma Corp
  • Class Anti-inflammatories; Anticoagulants; Antifibrotics; Antithrombotics; Peptides; Platelet membrane glycoproteins; Recombinant proteins
  • Mechanism of Action Protein C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Disseminated intravascular coagulation
  • Phase II Peripheral nervous system diseases
  • Discontinued Deep vein thrombosis; Idiopathic pulmonary fibrosis

Most Recent Events

  • 11 Dec 2024 Thrombomodulin alfa is still in phase III trials for Disseminated intravascular coagulation in Brazil, United Kingdom, Australia, Croatia (https://www.asahi-kasei.co.jp/pharma/en/research_development/pipeline/)
  • 25 Nov 2024 Thrombomodulin alfa is still in phase III development for Disseminated intravascular coagulation in Spain, USA, Taiwan, India, Argentina, Finland, Colombia, Germany, Israel and Russia (IV, Infusion) (Asahi Kasei Pharma Corp pipeline, November 2024)
  • 24 Feb 2022 Veloxis Pharmaceuticals plans a phase I trial for Colorectal cancer (Combination therapy, Metastatic disease) and Peripheral neuropathies (Chemotherapy-induced) in February 2022 (IV) (NCT05251727)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top